Research programme: small molecule therapeutics - InterX/Philochem/The Scripps Research Institute
Latest Information Update: 18 May 2022
At a glance
- Originator InterX; Philochem; The Scripps Research Institute
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Prostate cancer
Most Recent Events
- 12 May 2022 InterX has been acquired by NeoTX Therapeutics
- 23 Aug 2021 Philochem, InterX and The Scripps Research Institute agree to co-develop small molecule therapeutics for Prostate cancer (Late stage disease)
- 23 Aug 2021 Early research in Prostate cancer (Late-stage disease) in Switzerland (unspecified route) in August 2021